With this deal, Celldex is gaining a strong partner in the form of Bristol-Myers, a company with expertise in the field of immuno-oncology. Moreover, the deal terms look favorable – sharing of development costs and more importantly, the …
I think that if anything the reason the stock has moved around a little bit is there is a lot to interpret.” Celldex shares, which closed at $4.26, initially rose after the study results were announced before falling back to $3.90 in after hours trading ...
The Branford biotech firm CuraGen Corp., which recently completed its sale to ... one share cost less than a cup of Starbucks coffee — $1.44. Celldex trades on the Nasdaq Stock Market. Its shares closed at $5.26 Friday, up 6 percent …
Celldex Therapeutics Inc. (CLDX ... Recent event: -- On March 27, 2018, the Company closed the public offering of common stock and full exercise of underwriters' option to purchase additional shares. The shares were priced at $7.50 …
For example, Celldex Therapeutics, Inc. (NASDAQ: CLDX) just recently broke out above its $18 resistance. In that period of time that stock has already hit a high of more than $21. Another biotech name that just broke out this week, and …
Pfizer has decided to terminate a brain cancer vaccine partnership with Celldex Therapeutics ... Investors have been less enthusiastic and the company's stock sank 26.2% to $3.53.
Celldex Therapeutics, Inc. 's ( CLDX) shares continued to decline after the company reported a wider-than-expected loss for the first quarter of 2014. Shares, which declined 2.4% immediately after the release of first quarter results, slipped a …
Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced today that several clinical programs, including the Phase 2 ReACT study of RINTEGA® (rindopepimut) in patients with recurrent glioblastoma (GBM), will be presented at the 2015 …